Journal of Clinical Investigation · 2022 · 55 citations · 60 references
Life SciencesNeurologyNeuroscienceMitochondrial BiologyMolecular NeuroscienceNeurodegenerationAxonal DegenerationCharcot-marie-tooth DiseaseMitochondrial DiseaseMitochondrial DysfunctionMolecular Basis Of NeurodegenerationNeurodegenerative DiseasesAxon InjuryAxonal Hereditary NeuropathyMfn2 MutationsMfn2-related NeuropathyMitochondrial NeuropathologyMitochondrial Neuropathy ModelsMitofusin 2Muscle Atrophy Mechanisms
Charcot-Marie-Tooth disease type 2A (CMT2A) is an axonal neuropathy caused by mutations in the mitofusin 2 (MFN2) gene. MFN2 mutations result in profound mitochondrial abnormalities, but the mechanism underlying the axonal pathology is unknown. Sterile α and Toll/IL-1 receptor motif-containing 1 (SARM1), the central executioner of axon degeneration, can induce neuropathy and is activated by dysfunctional mitochondria. We tested the role of SARM1 in a rat model carrying a dominant CMT2A mutation (Mfn2H361Y) that exhibits progressive dying-back axonal degeneration, neuromuscular junction (NMJ) abnormalities, muscle atrophy, and mitochondrial abnormalities - all hallmarks of the human disease. We generated Sarm1-KO (Sarm1-/-) and Mfn2H361Y Sarm1 double-mutant rats and found that deletion of Sarm1 rescued axonal, synaptic, muscle, and functional phenotypes, demonstrating that SARM1 was responsible for much of the neuropathology in this model. Despite the presence of mutant MFN2 protein in these double-mutant rats, loss of SARM1 also dramatically suppressed many mitochondrial defects, including the number, size, and cristae density defects of synaptic mitochondria. This surprising finding indicates that dysfunctional mitochondria activated SARM1 and that activated SARM1 fed back on mitochondria to exacerbate the mitochondrial pathology. As such, this work identifies SARM1 inhibition as a therapeutic candidate for the treatment of CMT2A and other neurodegenerative diseases with prominent mitochondrial pathology.
60
dSarm/Sarm1 Is Required for Activation of an Injury-Induced Axon Death Pathway
Jeannette M. Osterloh, Jing Yang, Timothy M. Rooney et al. · Science · 2012 · 718 citations · Full text
Vesicular Glycolysis Provides On-Board Energy for Fast Axonal Transport
Diana Zala, María-Victoria Hinckelmann, Hua Yu et al. · Cell · 2013 · 462 citations · Full text